Acknowledges successful growth of the supply chain organisation over the past six years
Rx-360 has appointed Mark S. Paxton to the position of Chief Executive of the international pharmaceutical supply chain consortium.
This appointment follows the successful growth of the organisation since its foundation in 2009 in the aftermath of the adulterated heparin tragedy.
Paxton will provide leadership to an organisation of 300 volunteers from more than 100 institutions that are arranged in 17 working groups with activities in the US, Europe, China and India.
Rx-360’s first CEO will lead the consortium and its membership in executing the Board’s Strategic Plan, expanding its membership and creating global awareness of its central mission, which is to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within that chain.
Paxton joins Rx-360 from the US Food and Drug Administration where he led an international Strategic Programme focused on medical product quality and supply chain security under Asia-Pacific Economic Cooperation (APEC), a multi-lateral forum of governments to promote sustainable economic growth within the Asia-Pacific region.